ProQR Therapeutics is a clinical-stage biopharmaceutical company focused on the development of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa using its unique proprietary RNA repair platform technologies. ProQR Therapeutics was founded in 2012 and has been listed on NASDAQ since 2014.